Document Type

Journal Article

Publication Title

Seminars in Oncology Nursing

Volume

40

Issue

2

PubMed ID

38368204

Publisher

Elsevier

School

School of Medical and Health Sciences

RAS ID

70029

Funders

Royal Brisbane and Women’s Hospital foundation, Brisbane, Queensland

Comments

Spooner, A. J., Turner, J., Button, E., Yates, P., Kennedy, G., Butler, J., . . . Chan, R. J. (2024). Supporting cancer survivors following treatment for non-Hodgkin's and Hodgkin's lymphoma: A pilot study assessing the feasibility and process outcomes of a nurse-led intervention. Seminars in Oncology Nursing, 40(2), article 151592. https://doi.org/10.1016/j.soncn.2024.151592

Abstract

Objective: Lymphoma is the sixth most common cancer in Australia and comprises 2.8% of worldwide cancer diagnoses. Research targeting development and evaluation of post-treatment care for debilitating complications resulting from the disease and its treatment is limited. This study aimed to assess the feasibility and acceptability of a nurse-led survivorship intervention, post-treatment in Hodgkin's and non-Hodgkin's lymphoma survivors. Methods: A single-center, prospective, 3-arm, pilot, randomized controlled, parallel-group trial was used. People with lymphoma were recruited and randomized to the intervention (ENGAGE), education booklet only, or usual care arm. Participants receiving ENGAGE received an educational booklet and were offered 3 consultations (via various modes) with a cancer nurse to develop a survivorship care plan and healthcare goals. Participant distress and intervention acceptability was measured at baseline and 12-wk. Acceptability was measured via a satisfaction survey using a 11-point scale. Feasibility was measured using participation, retention rates, and process outcomes. Data were analyzed using descriptive statistics. Results: Thirty-four participants with HL and NHL were recruited to the study (11 = intervention, 11 = information only, 12 = usual care). Twenty-seven participants (79%) completed all time points from baseline to 12 wk. Seven (88%) of the 8 participants receiving ENGAGE completed all consultations using various modes to communicate with the nurse (videoconference 14/23, 61%; phone 5/23, 22%; face-to-face 4/23, 17%). Participants who completed the intervention were highly satisfied with ENGAGE. Conclusion: The ENGAGE intervention is feasible and highly acceptable for lymphoma survivors. These findings will inform a larger trial assessing effectiveness and cost effectiveness of ENGAGE.

DOI

10.1016/j.soncn.2024.151592

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Included in

Diseases Commons

Share

 
COinS